Program
zasocitinib
Also written as “Zasocitinib”, “TAK-279” and “NDI-034858 study drug”.
Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Crohn Disease · Hidradenitis Suppurativa · Vitiligo, led by Takeda.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 2613 open or running | phase 3since Oct 12, 2023 | Jul 19, 2021 | Feb 5, 2027phase 2 · NCT07244263 |
Also a collaborator on its studies: nimbus-lakshmi-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Jul 19, 2021.
- Mar 15, 2024Phase 3 study in PsoriasisNCT06323356 · 18 enrolled · Japan
- Aug 8, 2024Phase 3 study in Plaque PsoriasisNCT06550076 · 2,099 enrolled · United States, Argentina, Australia and more
- Oct 31, 20242 phase 3 studies in Arthritis, PsoriaticNCT06671496, NCT06671483
- Jan 2, 2025Phase 2 study in Crohn DiseaseNCT06764615 · 192 planned · United States, China, Czechia and more
- Jan 21, 2025Phase 1 study in Healthy VolunteersNCT06793943 · 78 enrolled · United States
- May 8, 2025Phase 3 study in Plaque PsoriasisNCT06973291 · 606 enrolled · United States, Bulgaria, Canada and more
- Aug 5, 2025Phase 2 study in Nonsegmental VitiligoNCT07108283 · 207 enrolled · United States, Canada, China and more
- Nov 17, 2025Phase 2 study in Hidradenitis SuppurativaNCT07244263 · 91 enrolled · United States, Australia, Canada and more
- Nov 18, 2025Phase 3 study in Plaque PsoriasisNCT07250802 · 210 planned · United States, China, Germany and more
- Dec 11, 2025Phase 3 study in Arthritis, PsoriaticNCT07286058 · 1,182 planned · United States, Argentina, Australia and more
- Feb 4, 2026Phase 2 study in Crohn DiseaseNCT07403968 · 20 planned · United Kingdom
- Aug 4, 2026Phase 3 study in PsoriasisNCT07752108 · 40 planned
- Oct 7, 2026Phase 3 study in Arthritis, PsoriaticNCT07871721 · 644 planned
- Nov 16, 2026Primary completion moved from 2033-01-24 to 2034-07-03Date moved laterphase 3 · +17 months · NCT07250802
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07244263
- Feb 17, 2027Primary completion: phase 2 study in Crohn DiseaseNCT06233461
- Mar 26, 2027Primary completion: phase 2 study in Nonsegmental VitiligoNCT07108283
- May 18, 2027Primary completion: phase 3 study in Arthritis, PsoriaticNCT06671496
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07871721Arthritis, Psoriatic | 3 | Not yet recruiting | Apr 18, 2030 | 644 |
| NCT07752108Psoriasis | 3 | Not yet recruiting | May 30, 2027 | 40 |
| NCT07403968Crohn Disease · United Kingdom | 2 | Recruiting | Mar 30, 2028 | 20 |
| NCT07286058Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 1,182 |
| NCT07250802Plaque Psoriasis · United States, China, Germany and more | 3 | Recruiting | Jul 3, 2034 | 210 |
| NCT07244263Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 5, 2027 | 91 |
| NCT07108283Nonsegmental Vitiligo · United States, Canada, China and more | 2 | Active, not recruiting | Mar 26, 2027 | 207 |
| NCT06973291Plaque Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Apr 22, 2026 | 606 |
| NCT06793943Healthy Volunteers · United States | 1 | Completed | Mar 11, 2025 | 78 |
| NCT06764615Crohn Disease · United States, China, Czechia and more | 2 | Recruiting | Dec 30, 2029 | 192 |
| NCT06671496Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 18, 2027 | 601 |
| NCT06671483Arthritis, Psoriatic · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | May 18, 2027 | 1,583 |
| NCT06550076Plaque Psoriasis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 5, 2029 | 2,099 |
| NCT06323356Psoriasis · Japan | 3 | Completed | Oct 17, 2025 | 18 |
| NCT06290050Healthy Volunteers · United States | 1 | Completed | May 3, 2024 | 20 |
| NCT06258265Healthy Volunteers · United States | 1 | Completed | Jun 25, 2024 | 120 |
| NCT06254950Colitis, Ulcerative · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jul 14, 2026 | 213 |
| NCT06233461Crohn Disease · United States, Australia, Belgium and more | 2 | Recruiting | Feb 17, 2027 | 268 |
| NCT06111547Healthy Volunteers · China | 1 | Completed | Jul 23, 2024 | 24 |
| NCT06108544Plaque Psoriasis · United States, Argentina, Bulgaria and more | 3 | Completed | Dec 6, 2024 | 1,108 |
| NCT06088043Plaque Psoriasis · United States, Australia, Canada and more | 3 | Completed | Jan 22, 2025 | 693 |
| NCT05995249Healthy Volunteers · United States | 1 | Completed | Dec 18, 2023 | 172 |
| NCT05992155Renal Insufficiency · United States | 1 | Completed | May 22, 2024 | 24 |
| NCT05976321Hepatic Impairment · United States | 1 | Completed | Apr 15, 2024 | 27 |
| NCT05153148Arthritis, Psoriatic · United States, Czechia, Germany and more | 2 | Completed | May 4, 2023 | 305 |
| NCT04999839Moderate to Severe Plaque Psoriasis · United States, Canada | 2 | Completed | Aug 19, 2022 | 259 |
How it is read
Names in the registry
- “Zasocitinib”, 12 entries
- “TAK-279”, 12 entries
- “NDI-034858 study drug”, 4 entries
- “Zasocitinib (Dose A)”, 1 entry
- “NDI-034858”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 8 studies
- Arthritis, Psoriatic, 5 studies
- Crohn Disease, 3 studies
- Hidradenitis Suppurativa, 1 study
- Vitiligo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.